RESUMO
INTRODUCTION: : 5-Aminolevulinic acid (5-ALA) is a naturally synthesized amino acid present in most plants as well as animals, and it is routinely consumed by humans. This brief report sought to describe the potential of 5-ALA and sodium-ferrous citrate (5-ALA/SFC) to ameliorate the course of coronavirus disease 2019 (COVID-19). AREAS COVERED: : Studies have shown that 5-ALA is converted to protoporphyrin IX (PPIX), then to heme. Recent studies have demonstrated that PPIX has antiviral effects against several viruses, including Zika virus, dengue virus, and influenza A virus. The anti-inflammatory effects of 5-ALA have also been reported in humans. Preliminary in vitro and clinical studies have shown that the combination of 5-ALA/SFC could reduce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-mediated insults. The SARS-CoV-2 genome contains guanine-quadruplex sequences, and the administration of 5-ALA/SFC can lead to the generation of porphyrins that have the ability to bind to guanine-quadruplexes and reduce the replication of SARS-CoV-2. Furthermore, 5-ALA is a metabolic precursor of heme, which is a potent inducer of the enzyme heme oxygenase-1, the levels of which are decreased in patients with severe COVID-19. Oral administration of 5-ALA/SFC induced heme oxygenase-1 in the peripheral blood of uninfected healthy individuals. EXPERT OPINION: : Based on the available information, it appears likely that 5-ALA/SFC has therapeutic value in clinically controlling SARS-CoV-2-mediated insults in COVID-19 patients. Multicenter randomized controlled trials are needed for determining the long-term clinical utility of 5-ALA/SFC.